JNJ

190.67

-0.69%↓

ABT

126.65

+0.42%↑

MDT

93.71

-0.66%↓

VEEV

294.02

+1.11%↑

A

147.88

+0.4%↑

JNJ

190.67

-0.69%↓

ABT

126.65

+0.42%↑

MDT

93.71

-0.66%↓

VEEV

294.02

+1.11%↑

A

147.88

+0.4%↑

JNJ

190.67

-0.69%↓

ABT

126.65

+0.42%↑

MDT

93.71

-0.66%↓

VEEV

294.02

+1.11%↑

A

147.88

+0.4%↑

JNJ

190.67

-0.69%↓

ABT

126.65

+0.42%↑

MDT

93.71

-0.66%↓

VEEV

294.02

+1.11%↑

A

147.88

+0.4%↑

JNJ

190.67

-0.69%↓

ABT

126.65

+0.42%↑

MDT

93.71

-0.66%↓

VEEV

294.02

+1.11%↑

A

147.88

+0.4%↑

Search

Actinium Pharmaceuticals Inc

Отворен

1.7 20.57

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.3900000000000001

Максимум

1.69

Ключови измерители

By Trading Economics

Приходи

9.1M

-6.9M

Марж на печалбата

-821.235

Служители

27

EBITDA

9.1M

-7.5M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+212.5% upside

Дивиденти

By Dow Jones

Следващи печалби

12.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-4.4M

47M

Предишно отваряне

-18.87

Предишно затваряне

1.7

Actinium Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2025 г., 20:49 ч. UTC

Печалби

Correction to Thermo Fisher Article on Oct. 22

23.10.2025 г., 23:51 ч. UTC

Пазарно говорене

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

23.10.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23.10.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23.10.2025 г., 22:58 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

23.10.2025 г., 22:57 ч. UTC

Пазарно говорене

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -2-

23.10.2025 г., 22:49 ч. UTC

Придобивния, сливания и поглъщания

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23.10.2025 г., 22:17 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23.10.2025 г., 21:41 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23.10.2025 г., 21:05 ч. UTC

Печалби

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

23.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

23.10.2025 г., 20:35 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23.10.2025 г., 20:28 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23.10.2025 г., 20:15 ч. UTC

Пазарно говорене
Печалби

Global Commodities Roundup: Market Talk

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Adj EPS $1.71

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q Sales $5.52B

23.10.2025 г., 20:10 ч. UTC

Печалби

Newmont Mining 3Q EPS $1.67

23.10.2025 г., 20:09 ч. UTC

Печалби

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

23.10.2025 г., 20:07 ч. UTC

Пазарно говорене
Печалби

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23.10.2025 г., 20:07 ч. UTC

Печалби

Blackstone Looks to IPOs for Investment Exits -- Update

23.10.2025 г., 20:05 ч. UTC

Печалби

Intel 3Q Gross Margin 38.2% >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel: 4Q Guidance Excludes Altera >INTC

23.10.2025 г., 20:04 ч. UTC

Печалби

Intel Sees 4Q Adj EPS 8c >INTC

Сравнение с други в отрасъла

Ценова промяна

Actinium Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

212.5% нагоре

12-месечна прогноза

Среден 4.5 USD  212.5%

Висок 5 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Actinium Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
help-icon Live chat